Literature DB >> 11120813

CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms.

D Askew1, R S Chu, A M Krieg, C V Harding.   

Abstract

Murine bone marrow cultured with GM-CSF produced dendritic cells (DCs) expressing MHC class II (MHC-II) but little CD40, CD80, or CD86. Oligodeoxynucleotides (ODN) containing CpG motifs enhanced DC maturation, increased MHC-II expression, and induced high levels of CD40, CD80, and CD86. When added with Ag to DCs for 24 h, CpG ODN enhanced Ag processing, and the half-life of peptide:MHC-II complexes was increased. However, Ag processing was only transiently enhanced, and exposure of DCs to CpG ODN for 48 h blocked processing of hen egg lysozyme (HEL) to HEL(48-61):I-A(k) complexes. Processing of this epitope required newly synthesized MHC-II and was blocked by brefeldin A (BFA), suggesting that reduced MHC-II synthesis could explain decreased processing. Real-time quantitative PCR confirmed that CpG ODN decreased I-A(beta)(k) mRNA in DCs. In contrast, RNase(42-56):I-A(k) complexes were generated via a different processing mechanism that involved recycling MHC-II and was partially resistant to BFA. Processing of RNase(42-56):I-A(k) persisted, although at reduced levels, after CpG-induced maturation of DCs, and this residual processing by mature DCs was completely resistant to BFA. Changes in endocytosis, which was transiently enhanced and subsequently suppressed by CpG ODN, may affect Ag processing by both nascent and recycling MHC-II mechanisms. In summary, CpG ODN induce DC maturation, transiently increase Ag processing, and increase the half-life of peptide-MHC-II complexes to sustain subsequent presentation. Processing mechanisms that require nascent MHC-II are subsequently lost, but those that use recycling MHC-II persist even in fully mature DCs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11120813     DOI: 10.4049/jimmunol.165.12.6889

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  38 in total

1.  CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies.

Authors:  R S Chu; T McCool; N S Greenspan; J R Schreiber; C V Harding
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

2.  Stereotyped and specific gene expression programs in human innate immune responses to bacteria.

Authors:  Jennifer C Boldrick; Ash A Alizadeh; Maximilian Diehn; Sandrine Dudoit; Chih Long Liu; Christopher E Belcher; David Botstein; Louis M Staudt; Patrick O Brown; David A Relman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

3.  TLR7 and TLR9 ligands regulate antigen presentation by macrophages.

Authors:  Teja Celhar; Selma Pereira-Lopes; Susannah I Thornhill; Hui Yin Lee; Manprit K Dhillon; Michael Poidinger; John E Connolly; Lina H K Lim; Subhra K Biswas; Anna-Marie Fairhurst
Journal:  Int Immunol       Date:  2015-11-13       Impact factor: 4.823

4.  Invariant chain modulates HLA class II protein recycling and peptide presentation in nonprofessional antigen presenting cells.

Authors:  Azizul Haque; Laela M Hajiaghamohseni; Ping Li; Katherine Toomy; Janice S Blum
Journal:  Cell Immunol       Date:  2007-12-11       Impact factor: 4.868

5.  Dendritic cell preactivation impairs MHC class II presentation of vaccines and endogenous viral antigens.

Authors:  Louise J Young; Nicholas S Wilson; Petra Schnorrer; Adele Mount; Rachel J Lundie; Nicole L La Gruta; Brendan S Crabb; Gabrielle T Belz; William R Heath; Jose A Villadangos
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-31       Impact factor: 11.205

6.  CpG-oligodeoxynucleotide is a potent adjuvant with an Entamoeba histolytica Gal-inhibitable lectin vaccine against amoebic liver abscess in gerbils.

Authors:  Catherine P A Ivory; Kathy Keller; Kris Chadee
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

7.  Synergistic effect of Nod1 and Nod2 agonists with toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells.

Authors:  Hiroyuki Tada; Setsuya Aiba; Ken-Ichiro Shibata; Toshiaki Ohteki; Haruhiko Takada
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

8.  Type I IFN drives a distinctive dendritic cell maturation phenotype that allows continued class II MHC synthesis and antigen processing.

Authors:  Daimon P Simmons; Pamela A Wearsch; David H Canaday; Howard J Meyerson; Yi C Liu; Ying Wang; W Henry Boom; Clifford V Harding
Journal:  J Immunol       Date:  2012-02-27       Impact factor: 5.422

9.  Enhanced immunogenicity of pneumococcal surface adhesin A by genetic fusion to cytokines and evaluation of protective immunity in mice.

Authors:  Dennis O Gor; Xuedong Ding; Qing Li; John R Schreiber; Michael Dubinsky; Neil S Greenspan
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

10.  Evaluation of protective effect of multi-epitope DNA vaccine encoding six antigen segments of Toxoplasma gondii in mice.

Authors:  Shan Liu; Lin Shi; Yan-bin Cheng; Gui-xiang Fan; Hui-xun Ren; Yu-kang Yuan
Journal:  Parasitol Res       Date:  2009-03-14       Impact factor: 2.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.